KMKonosuke Morimoto

Konosuke Morimoto

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Konosuke Morimoto has a total of 258 co-authors. Here are the top co-authors by number of shared publications:

  • Masayuki Ishida

    Department of Infectious Disease Medicine, Department of Respiratory Medicine Chikamori Hospital Kochi Japan

    14 shared publications
  • Motoi Suzuki

    Department of Clinical Medicine, Institute of Tropical Medicine, Nagasaki University, Nagasaki 852-8523, Japan

    13 shared publications
  • Koya Ariyoshi

    Department of Clinical Medicine, Institute of Tropical Medicine Nagasaki University Nagasaki Japan

    10 shared publications
  • Norichika Asoh

    Department of Internal Medicine Juzenkai Hospital Nagasaki Japan

    10 shared publications
  • Bhim Gopal Dhoubhadel

    Department of Respiratory Infections, Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan; School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki, Japan

    9 shared publications
  • Eiichiro Sando

    Kita-Fukushima Medical Center

    7 shared publications

Latest Publications

  • Open Access

    Pneumococcal carriage and serotype distribution among residents and healthcare workers in long-term care facilities in Japan during the COVID-19 pandemic

    by Haruka Maeda, Bhim Gopal Dhoubhadel, Koji Yoshida, Shogo Akabame, Hirotomo Yamanashi, Konosuke Morimoto

  • Open Access

    Incidence of RSV‐ and Influenza‐Associated Hospitalizations With Community‐Acquired Pneumonia and Other Acute Respiratory Infection Among Adults in Japan in 2022–2024: APSG‐J2 Study

    by Haruka Maeda, Shingo Masuda, Bhim Gopal Dhoubhadel, Yuka Fujita, Yuji Akiba, Yutaka Nishigaki, Kei Nakashima, Hiroyuki Ito, Masayuki Nogi, Yoshihito Otsuka, et al.

    Background: Quantifying the burden of respiratory syncytial virus (RSV) in adults is challenging compared to influenza, and data among older adults remain scarce in Japan. Country‐specific evidence is essential to support RSV vaccination policy. Methods: This prospective, multicenter study (APSG‐J2) targeted hospitalized adults with community‐acquired pneumonia (CAP) and other acute respiratory infections (ARI) in seven community hospitals across four catchment areas in Japan between September 2022 and August 2024. Respiratory samples were analyzed using a multiplex polymerase chain reaction (PCR) kit to detect RSV and influenza. Incidence rates of RSV‐ and influenza‐associated hospitalizations were estimated using study data and national statistics, stratified by age and region. Results: Among 3047 hospitalized patients with CAP/ARI, 1499 (49.2%) underwent multiplex PCR testing. RSV and influenza were detected in 2.8% and 3.3% of tested patients, respectively. The incidences of RSV‐associated CAP/ARI hospitalizations among adults aged ≥ 65 years were 29 and 36 per 100,000 person‐years in the first and second years, respectively, with higher incidences among those aged ≥ 85 years (150 and 131 per 100,000 person‐years). Influenza incidence increased markedly in the second year (from 11 to 71 per 100,000 person‐years for adults age ≥ 65 years), possibly reflecting post‐COVID‐19 transmission changes. Conclusions: In this multicenter study, we estimated the incidence of RSV‐ and influenza‐associated hospitalizations among adults in Japan. The findings indicated that the incidence increased with age, and influenza‐associated hospitalizations increased in the second year. Continued surveillance is essential to accurately assess RSV burden in the adult population.


  • Open Access

    Genomic analysis of the genetic background underlying Streptococcus pneumoniae beta-lactam nonsusceptibility in central Vietnam: increased beta-lactam nonsusceptibility and dynamics of the pbp2x gene

    by Hiroshi Fujii, Mitsuhiko Sato, Hien Anh Thi Nguyen, Huong Thi Thu Vu, Satoshi Kakiuchi, Bhim Gopal Dhoubhadel, Shota Nakamura, Daisuke Motooka, Yoshitoshi Ogura, Satoshi Nakano, et al.

    We previously reported alarmingly high carriage rates of Streptococcus pneumoniae (SP) serotype 19F and serogroup 6 isolates, which were not susceptible to

  • Open Access

    Non-Vaccine Serotype Replacement and Subdominant Persistence of Vaccine Types in Nepalese Infants Following PCV10 Introduction

    by Fleurette Mbuyakala Domai, Dhruba Shrestha, Raj Kumar Shrestha, Monika Thimi, Desmond Opoku Ntiamoah, Yumiko Hayashi, Chris Smith, Yoshinao Kubo, Shunmay Yeung, Motoi Suzuki, et al.

    Background: Streptococcus pneumoniae is a leading cause of child mortality in Nepal despite the introduction of the 10-valent pneumococcal conjugate vaccine (PCV10). Vaccine effectiveness is threatened by the emergence of non-vaccine serotypes (NVTs) and the multiple serotypes carriage which often fail to be detected by traditional methods. We aimed to study changes in serotype distribution before and after PCV10 immunization among infants, including serotype dominance in Nepalese infants in the post-vaccine era. Methods: We enrolled infants in a longitudinal cohort study (2020–2022) conducted in Bhaktapur, Nepal. Nasopharyngeal swabs were collected before PCV10 dose 1 (6 weeks) and at 9 and 12 months post-immunization. We used a sensitive nanofluidic qPCR platform to detect multiple serotypes and establish their hierarchy by quantifying the bacterial load of each strain. Inverse Probability Weighting (IPW) adjusted risk factor analysis was used to account for loss to follow-up. Results: PCV10 successfully reduced vaccine-type (VT) carriage, declining sharply from 32.8% at 6 weeks to 4.8% at 12 months. VTs were pushed from being the dominant strain to occupying subdominant roles in co-colonization. Conversely, NVTs rapidly filled the vacated niche, showing a significant increase in their dominant status (p < 0.001). The most common replacing NVTs that rose to dominance were 35B, 19A, 6C/6D, and 15B/15C. Significant risk factors for carriage included older infancy (aOR 3.4, 95%CI: 2.6–4.5 at 9 months), a household kitchen in the living area (aOR 1.4, 95%CI: 1.0–1.9), and winter (aOR 1.7, 95%CI: 1.5–2.7) and pre-monsoon seasons (aOR 2.0, 95%CI: 1.5–2.8). Conclusions: While PCV10 reduced overall VT circulation, the persistence of VTs in subdominant niches creates a continuous reservoir for potential re-emergence and antibiotic resistance. This clear hierarchical shift in dominance towards NVTs underscores the urgent need for a public health strategy that includes the adoption of a higher-valent PCV to provide broader protection, and interventions targeting environmental risk factors are essential to sustain long-term reductions in pneumococcal colonization.


  • Open Access

    Serotype distribution among adults with community-acquired pneumococcal pneumonia in Japan between 2019 and 2022: A multicenter observational study

    by Haruka Maeda, Isao Ito, Eiichiro Sando, Nobuyoshi Hamao, Masahiro Shirata, Bhim Gopal Dhoubhadel, Desmond Opoku Ntiamoah, Issei Oi, Kensuke Nishioka, Hiroshi Fujii, et al.

    Streptococcus pneumoniae is a leading cause of community-acquired pneumonia (CAP) in adults. With the introduction of pneumococcal conjugate vaccines (PCVs) into pediatric national immunization programs, the serotype distribution of pneumococcal disease among adults has changed due to indirect effect. In Japan, PCV15 and PCV20 have been introduced, and PCV21 is under review for approval in adults. This multicenter observational study assessed pneumococcal serotypes in 583 adult patients with community-acquired, culture-positive pneumococcal pneumonia from May 2019 to December 2022. Pneumococcal isolates were serotyped using the Quellung reaction. The median patient age was 74 years (interquartile range: 66-82 years), 383 (65.7%) patients were male, 387 (66.4%) patients had one or more underlying medical conditions, 425 patients (72.9%) were hospitalized, and 305 (52.3%) had a CURB-65 score ≥2. The most common serotypes were serotype 3 (12.5%), 35B (12.0%), 15A (7.7%), 11A (6.7%), and 23A (6.3%). The proportion of serotypes covered by PCV13, PCV15, PCV20, PPSV23, and PCV21 were 24.0, 28.0, 43.7, 44.1, and 71.9%, respectively. The proportions of vaccine-covered serotypes were similar between patients aged <65 and ≥65 years. Serotype 3 was more prevalent among patients living in nursing homes (25.9%) compared with those living at home (11.2%). The proportions of PCV20- and PCV21-covered serotypes suggest that these new vaccines may offer additional protection against adult pneumococcal pneumonia. Given the availability of newly developed PCVs for adults in Japan, reassessing the optimal pneumococcal vaccination policy for adults is warranted.


  • Open Access

    Estimating Incidence of Respiratory Syncytial Virus- and Influenza Virus-Associated Hospitalizations with Community-Acquired Pneumonia and Other Acute Respiratory Infection Among Adults in Japan During and After the COVID-19 Era: A Multicenter Active Surveillance Study (APSG-J2)

    by Haruka Maeda, Shingo Masuda, Bhim Gopal Dhoubhadel, Yuka Fujita, Yuji Akiba, Yutaka Nishigaki, Kei Nakashima, Hiroyuki Ito, Masayuki Nogi, Yoshihito Otsuka, et al.

    Background: Quantifying the burden of respiratory syncytial virus (RSV) in adults is challenging compared to influenza, and data among older adults remain scarce in Japan. Country-specific evidence is essential to support RSV vaccination policy. Methods: This prospective, multicenter study (APSG-J2) targeted hospitalized adults with community-acquired pneumonia (CAP) and other acute respiratory infection (ARI) in seven community-hospitals across four catchment areas in Japan between September 2022 and August 2024. Respiratory samples were analyzed using a multiplex polymerase chain reaction (PCR) kit to detect RSV and influenza. Incidence rates of RSV- and influenza-associated hospitalizations were estimated using study data and national statistics, stratified by age and region. Results: Among 3,047 hospitalized patients with CAP/ARI, 1,502 (49.3%) underwent multiplex PCR testing. RSV and influenza were detected in 2.8% and 3.3% of tested patients, respectively. The incidences of RSV-associated CAP/ARI hospitalizations among adults aged ≥65 years were 29 and 36 per 100,000 person-years in the first and second years, respectively, with higher incidences among those aged ≥85 years (150 and 131 per 100,000 person-years). Influenza incidence increased markedly in the second year (from 11 to 71 per 100,000 person-years for adults age ≥65 years), possibly reflecting post-COVID-19 transmission changes. Conclusions: This is the first active surveillance study in Japan to estimate RSV- and influenza-associated hospitalization incidence among adults during and after the COVID-19 era. The results may still be influenced by the lingering effects of COVID-19 restrictions on social interaction. Continued surveillance is essential to accurately assess RSV burden in the adult population.


  • Open Access

    Serotype distribution among adults with community-acquired pneumococcal pneumonia in Japan between 2019 and 2022: A multicenter observational study

    by Haruka Maeda, Isao Ito, Eiichiro Sando, Nobuyoshi Hamao, Masahiro Shirata, Bhim Gopal Dhoubhadel, Desmond Opoku Ntiamoah, Issei Oi, Kensuke Nishioka, Hiroshi Fujii, et al.

    Background: Streptococcus pneumoniae is a leading cause of community-acquired pneumonia in adults. With the introduction of pneumococcal conjugate vaccines (PCVs) into pediatric national immunization programs, the serotype distribution of pneumococcal disease among adults has changed due to herd immunity. In Japan, PCV15 and PCV20 have been introduced, and PCV21 has been under review for approval in adults. This study aimed to assess the distribution of pneumococcal serotypes among adults with pneumococcal pneumonia in Japan between May 2019 and December 2022. Methods: This multicenter observational study enrolled patients aged ≥18 years with community-acquired, culture-positive pneumococcal pneumonia from May 2019 to December 2022. Pneumococcal isolates were serotyped using the Quellung reaction, and proportions of individual and vaccine-covered serotypes were analyzed. Results: A total of 583 adult patients with pneumococcal pneumonia were included. The median age was 74 years (interquartile range: 66–82 years), 383 (65.7%) patients were male, and 387 (66.4%) patients had one or more underlying medical conditions. The most common serotypes were serotype 3 (12.5%), 35B (12.0%), 15A (7.7%), 11A (6.7%), and 23A (6.3%). The proportion of serotypes covered by PCV13, PCV15, PCV20, PPSV23, and PCV21 were 24.0, 28.0, 43.7, 44.1, and 71.9%, respectively. The proportions of vaccine-covered serotypes were similar between patients aged <65 and ≥65 years. Notably, serotype 3 was more prevalent among patients living in nursing homes (25.9%) compared with those living at home (11.2%). Conclusion: Serotypes 3 and 35B were the most common in adults with pneumococcal pneumonia in Japan during the study period. The proportions of PCV20- and PCV21-covered serotypes suggest that these new vaccines may offer additional protection against adult pneumococcal pneumonia. With the availability of newly developed PCVs for adults in Japan, it is time to reassess the optimal pneumococcal vaccination policy for adults.


  • Open Access

    Clinically defined aspiration pneumonia is an independent risk factor associated with long-term hospital stay: a prospective cohort study

    by Takao Wakabayashi, Sugihiro Hamaguchi, Konosuke Morimoto

    Background: Long-term hospital stay is associated with functional decline in patients with pneumonia, especially in the elderly. Among elderly patients with pneumonia, aspiration pneumonia is a major category. Clinical definition is usually used because it can occur without apparent aspiration episodes. It is still not clear whether a long-term hospital stay is due to aspiration pneumonia itself caused by underlying oropharyngeal dysfunction or simply due to functional decline in elderly patients with multiple comorbidities during acute infection. The aim of this study is to identify whether clinically defined aspiration pneumonia itself was associated with a long-term hospital stay.Methods: A prospective observational study on community-acquired (CAP) or healthcare-associated pneumonia (HCAP) was conducted from January 2012 through January 2014. Aspiration pneumonia was clinically defined as pneumonia not only occurring in patients after documented aspiration episodes, but also occurring in those with underlying oropharyngeal dysfunction: chronic disturbances of consciousness and/or chronic neuromuscular diseases. We defined thirty-day hospital stay as a long-term hospital stay and compared it with logistic regression analysis. Potential confounders included age, sex, HCAP, body mass index (BMI), long-term bed-ridden state, heart failure, cerebrovascular disorders, dementia, antipsychotics use, hypnotics use, and CURB score which is a clinical prediction tool used to assess the severity, standing for; C (presence of Confusion), U (high blood Urea nitrogen level), R (high Respiratory rate), and B (low Blood pressure). In a sub-analysis, we also explored factors associated with long-term hospital stay in patients with aspiration pneumonia.Results: Of 2,795 patients, 878 (31.4%) had aspiration pneumonia. After adjusting potential confounders, the aspiration pneumonia itself was significantly associated with long-term hospital stay (adjusted odds ratio 1.44; 95% confidence interval 1.09—1.89,p < 0.01), as were higher age, male sex, high CURB score, HCAP, low BMI, heart failure, cerebrovascular disease, and antipsychotics use. Sub-analysis revealed factors associated with long-term hospital stay in the aspiration pneumonia, which included male sex, and multi-lobar chest X-ray involvement.Conclusions: Clinically defined aspiration pneumonia itself was independently associated with long-term hospital stay. This result could potentially lead to specific rehabilitation strategies for pneumonia patients with underlying oropharyngeal dysfunction.


  • Open Access

    Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the SARS-CoV-2 Omicron BA.1 and BA.2 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS)

    by Haruka Maeda, Nobuo Saito, Ataru Igarashi, Masayuki Ishida, Mayumi Terada, Takayasu Ito, Hideko Ikeda, Hiroshi Kamura, Iori Motohashi, Yuya Kimura, et al.

    Evaluating COVID-19 vaccine effectiveness (VE) domestically is crucial for assessing and determining national vaccination policy. This study aimed to evaluate VE of mRNA COVID-19 vaccines in Japan....